HMQ‑T‑F2 suppresses migration of the human cervical cancer HeLa cells by reversing EMT via the PI3K/Akt signaling pathway

Dai,Bingling; Yu,Runze; Fan,Mengying; Yang,Tianfeng; Wang,Bo; Zhang,Yanmin

doi:10.3892/or.2019.7245

HMQ‑T‑F2 suppresses migration of the human cervical cancer HeLa cells by reversing EMT via the PI3K/Akt signaling pathway

Authors:
- Bingling Dai
- Runze Yu
- Mengying Fan
- Tianfeng Yang
- Bo Wang
- Yanmin Zhang
View Affiliations

Affiliations: School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: July 23, 2019 https://doi.org/10.3892/or.2019.7245
Pages: 1451-1458

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epithelial‑mesenchymal transition (EMT) is closely related to tumor metastasis, and offers insight into novel strategies for cancer treatment. HMQ‑T‑F2 (F2) is a taspine derivative, which has excellent anticancer activity in human cervical cancer. The present study aimed to evaluate the effect of F2 on in vitro migration of HeLa cells. The present data demonstrated that F2 inhibited migration of HeLa cells by negatively regulating the Wnt signaling pathway and reversing EMT. F2 not only mediated Frizzled8, p‑LRP6 and LRP6 expression, but also downregulated the phosphorylation of GSK3β, and concurrently decreased the nucleus protein expression of MMP2, MMP3, MMP7, MMP9, and c‑Myc. In addition, the expression of N‑cadherin, vimentin, Snail and HIF‑1α were downregulated and that of E‑cadherin was upregulated after F2 treatment. F2 was also associated with the downregulation of the PI3K/Akt/mTOR signaling pathways. Notably, F2 induced HeLa cell accumulation at the S phase and cell apoptosis. These results provide evidence that F2 inhibits HeLa cell migration, proliferation and promotes apoptosis. It also reverses EMT, potentially via the PI3K/Akt signaling pathway. Therefore, F2 may be a potential therapeutic reagent against cervical cancer.

View Figures

View References

1	Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A and Colombo N; ESMO Guidelines Committee, : Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 28 (Suppl):iv72–iv83. 2017. View Article : Google Scholar : PubMed/NCBI
2	Fomenko Y, Cialkowska-Rysz A, Muravlyova L, Sirota V and Sapar B: Assessment of direct results of cervical cancer combined treatment. Georgian Med News. 21–24. 2018.PubMed/NCBI
3	Zhang L, Qian H, Sha M, Luan Z, Lin M, Yuan D, Li X, Huang J and Ye L: Downregulation of HOTAIR expression mediated anti-metastatic effect of artesunate on cervical cancer by inhibiting COX-2 expression. PLoS One. 11:e01648382016. View Article : Google Scholar : PubMed/NCBI
4	Chu SC, Yu CC, Hsu LS, Chen KS, Su MY and Chen PN: Berberine reverses epithelial-tomesenchymal transition and inhibits metastasis and tumor-induced angiogenesis in human cervical cancer cells. Mol Pharmacol. 86:609–623. 2014. View Article : Google Scholar : PubMed/NCBI
5	Lee JM, Dedhar S, Kalluri R and Thompson EW: The epithelial-mesenchymal transition: New insights in signaling, development, and disease. J Cell Biol. 172:973–981. 2006. View Article : Google Scholar : PubMed/NCBI
6	Wang Z, He S, Guo P, Guo X and Zheng J: Microrna-1297 inhibits metastasis and epithelial-mesenchymal transition by targeting aeg-1 in cervical cancer. Oncol Rep. 38:3121–3129. 2017. View Article : Google Scholar : PubMed/NCBI
7	Sathyanarayanan A, Chandrasekaran KS and Karunagaran D: Microrna-145 modulates epithelial-mesenchymal transition and suppresses proliferation, migration and invasion by targeting sip1 in human cervical cancer cells. Cell Oncol (Dordr). 40:119–131. 2017. View Article : Google Scholar : PubMed/NCBI
8	Qi X, Zhang L and Lu X: New insights into the epithelial-to-mesenchymal transition in cancer. Trend Pharmacol Sci. 37:246–248. 2016. View Article : Google Scholar
9	Franco-Chuaire ML, Magda Carolina SC and Chuaire-Noack L: Epithelial mesenchymal transition (EMT): Principles and clinical impact in cancer therapy. Invest Clin. 54:186–205. 2013.PubMed/NCBI
10	Wang Y, Wen M, Kwon Y, Xu Y, Liu Y, Zhang P, He X, Wang Q, Huang Y, Jen KY, et al: CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. Cancer Res. 74:520–531. 2014. View Article : Google Scholar : PubMed/NCBI
11	Li HQ and Ke Y: Mechanism of epithelial-mesenchymal transition. Chin Pharmacol Bull. 33:1342–1344. 2017.
12	Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y and Johnson KR: Cadherin switching. J Cell Sci. 121:727–735. 2008. View Article : Google Scholar : PubMed/NCBI
13	Gos M, Miloszewska J and Przybyszewska M: Epithelial- mesenchymal transition in cancer progression. Postepy Biochem. 55:121–128. 2009.(In Polish). PubMed/NCBI
14	Sethi S, Macoska J, Chen W and Sarkar FH: Molecular signature of epithelialmesenchymal transition (EMT) in human prostate cancer bone metastasis. Am J Transl Res. 3:90–99. 2010.PubMed/NCBI
15	Li W, Li S, Deng L, Yang S, Li M, Long S, Chen S, Lin F and Xiao L: Decreased MT1-MMP in gastric cancer suppressed cell migration and invasion via regulating MMPs and EMT. Tumor Biol. 36:6883–6889. 2015. View Article : Google Scholar
16	Hugo HJ, Kokkinos MI, Blick T, Ackland ML, Thompson EW and Newgreen DF: Defining the E-cadherin repressor interactome in epithelial mesenchymal transition: The PM C42 model as a case study. Cells Tissues Organs. 193:23–40. 2011. View Article : Google Scholar : PubMed/NCBI
17	Nguyen PT, Kudo Y, Yoshida M, Iizuka S, Ogawa I and Takata T: N-cadherin expression is correlated with metastasis of spindle cell carcinoma of head and neck region. J Oral Pathol Med. 40:77–82. 2011. View Article : Google Scholar : PubMed/NCBI
18	Wu Y and Zhou BP: TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br J Cancer. 102:639–644. 2010. View Article : Google Scholar : PubMed/NCBI
19	Wang YL, Liu HF, Shi XJ and Wang Y: Antiproliferative activity of Farnesol in HeLa cervical cancer cells is mediated via apoptosis induction, loss of mitochondrial membrane protential and PI3K/Akt signaling pathway. J Buon. 23:752–757. 2018.PubMed/NCBI
20	Dai B, Yang T, Ma Y, Ma N, Shi X, Zhang D, Zhang J and Zhang Y: HMQ-T-F2 exert antitumour effects by upregulation of Axin in human cervical HeLa cells. J Cell Mol Med. 22:2955–2959. 2018. View Article : Google Scholar : PubMed/NCBI
21	Beavon IR: The E-cadherin-catenin complex in tumour metastasis: Structure, function and regulation. Eur J Cancer. 36:1607–1620. 2000. View Article : Google Scholar : PubMed/NCBI
22	Bahnson A, Athanassiou C, Koebler D, Qian L, Shun T, Shields D, Yu H, Wang H, Goff J, Cheng T, et al: Automated measurement of cell motility and proliferation. BMC Cell Biol. 6:192005. View Article : Google Scholar : PubMed/NCBI
23	Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 10:721–732. 2003. View Article : Google Scholar
24	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
25	Yan J, Zhang Y, Ren C, Shi W and Chen L: Involvement of nuclear protein C23 in activation of EGFR signaling in cervical cancer. Tumour Biol. 37:905–910. 2016. View Article : Google Scholar : PubMed/NCBI
26	Yee GP, de Souza P and Khachigian LM: Current and potential treatments for cervical cancer. Curr Cancer Drug Targets. 13:205–220. 2013. View Article : Google Scholar : PubMed/NCBI
27	Sánchez-Tilló E, de Barrios O, Siles L, Cuatrecasas M, Castells A and Postigo A: β-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci USA. 108:19204–19209. 2011. View Article : Google Scholar : PubMed/NCBI
28	Solanas G, Porta-de-la-Riva M, Agustí C, Casagolda D, Sánchez-Aguilera F, Larriba MJ, Pons F, Peiró S, Escrivà M, Muñoz A, et al: E-cadherin controls beta-catenin and NF-kappaB transcriptional activity in mesenchymal gene expression. J Cell Sci. 121:2224–2234. 2008. View Article : Google Scholar : PubMed/NCBI
29	Qureshi R, Arora H and Rizvi MA: EMT in cervical cancer: Itsrole in tumour progression and response to therapy. Cancer Lett. 356:321–331. 2015. View Article : Google Scholar : PubMed/NCBI
30	Kwon YJ, Ye DJ, Baek HS and Chun YJ: 7,12-Dimethylbenz[α]anthracene increases cell proliferation and invasion through induction of Wnt/β-catenin signaling and EMT process. Environ Toxicol. 33:729–742. 2018. View Article : Google Scholar : PubMed/NCBI
31	Höckel M and Vaupel P: Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer. 93:266–276. 2001. View Article : Google Scholar
32	Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ and van der Wall E: Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer. 97:1573–1581. 2003. View Article : Google Scholar : PubMed/NCBI
33	Birner P, Schindl M, Obermair A, Breitenecker G and Oberhuber G: Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: Its impact on prognosis and on response to chemotherapy. Clin Cancer Res. 7:1661–1668. 2001.PubMed/NCBI
34	Song IS, Wang AG, Yoon SY, Kim JM, Kim JH, Lee DS and Kim NS: Regulation of glucose metabolism-related genes and VEGF by HIF-1alpha and HIF-1beta, but not HIF-2alpha, in gastric cancer. Exp Mol Med. 41:51–58. 2009. View Article : Google Scholar : PubMed/NCBI
35	Porta C, Paglino C and Mosca A: Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 4:642014. View Article : Google Scholar : PubMed/NCBI
36	Bachelder RE, Yoon SO, Franci C, de Herreros AG and Mercurio AM: Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: Implications for the epithelial to mensenchymal transition. J Cell Biol. 168:29–33. 2005. View Article : Google Scholar : PubMed/NCBI